Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
How does an ∏2A receptor agonist improve attention?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 95 - 118Publisher: Cambridge University PressPrint publication year: 2023
References
Barkley, R. A., DuPaul, G. J., McMurray, M. B. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991; 87(4): 519–31. https://doi.org/10.1542/peds.87.4.519Google Scholar
Bousquet, P., Hudson, A., García-Sevilla, J. A., Li, J. X. Imidazoline receptor system: the past, the present, and the future. Pharmacol Rev 2020; 72(1): 50–79. https://doi.org/10.1124/pr.118.016311Google Scholar
Cortese, S., Adamo, N., Del Giovane, C., et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry 2018; 5(9): 519–31. https://doi.org/10.1016/S2215-0366(18)30269-4Google Scholar
Cortese, S., Holtmann, M., Banaschewski, T., et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry Allied Discip 2013; 54(3): 227–46. https://doi.org/10.1111/jcpp.12036Google Scholar
Farhat, L. C., Flores, J. M., Behling, E., et al. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molec Psychiatry 2022: 27(3): 1562–72. https://doi.org/10.1038/s41380-021-01391-9Google Scholar
Hammerness, P. G., Perrin, J. M., Shelley-Abrahamson, R., Wilens, T. E. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011; 50(10): 978–90. https://doi.org/10.1016/j.jaac.2011.07.018Google Scholar
Martin, P., Satin, L., Vince, B. D., et al. Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13–17 years with attention-deficit/hyperactivity disorder. Clin Pharmacol Drug Devel 2014; 3(4): 252–61. https://doi.org/10.1002/cpdd.124Google ScholarPubMed
Ming, X., Mulvey, M., Mohanty, S., Patel, V. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther 2011; 2: 105–12. https://doi.org/10.2147/AHMT.S15672Google Scholar
Newcorn, J. H., Stein, M. A., Cooper, K. M. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. J Child Adolesc Psychopharmacol 2010; 20(3): 187–96. https://doi.org/10.1089/cap.2009.0102Google Scholar
Sallee, F. R., Kollins, S. H., Wigal, T. L. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2012; 22(3): 206–14. https://doi.org/10.1089/cap.2010.0135Google Scholar
Sallee, F. R., McGough, J., Wigal, T., et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48(2): 155–65. https://doi.org/10.1097/CHI.0b013e318191769eGoogle Scholar
Sayer, G. R., McGough, J. J., Levitt, J., et al. Acute and long-term cardiovascular effects of stimulant, guanfacine, and combination therapy for attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2016; 26(10): 882–88. https://doi.org/10.1089/cap.2015.0264Google Scholar
Stein, M. A., Sarampote, C. S., Waldman, I. D., et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112(5): e404. https://doi.org/10.1542/peds.112.5.e404Google Scholar
Strawn, J. R., Compton, S. N., Robertson, B., et al. Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol 2017; 27 (1): 29–37. https://doi.org/10.1089/cap.2016.0132Google Scholar
Strawn, J. R., Prakash, A., Zhang, Q., et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 2015; 54(4): 283–93. https://doi.org/10.1016/j.jaac.2015.01.008Google Scholar
Stuckelman, Z. D., Mulqueen, J. M., Ferracioli-Oda, E., et al. Risk of irritability with psychostimulant treatment in children with ADHD: a meta-analysis. J Clin Psychiatry 2017; 78(6): e648–55. https://doi.org/10.4088/JCP.15r10601Google Scholar
Wilens, T. E., Bukstein, O., Brams, M., et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51(1): 74–85. https://doi.org/10.1016/j.jaac.2011.10.012Google Scholar
Wilens, T. E., Robertson, B., Sikirica, V., et al. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2015; 54(11): 916–25. https://doi.org/10.1016/j.jaac.2015.08.016Google Scholar